FACULTY
Linda C. Laux, MD
Associate Division Head, Neurology
Section Head, Lurie Children’s Epilepsy Center
Ann & Robert H. Lurie Children’s Hospital of Chicago
Lorna S. and James P. Langdon Chair in Pediatric Neurology
Associate Professor of Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL
Joseph E. Sullivan, MD, FAES
Murphy Parker Endowed Professorship in Pediatric Epilepsy
Professor of Neurology & Pediatrics
University of California San Francisco
Director, Benioff Children’s Hospital Pediatric Epilepsy Center of Excellence
Co-Director, PISCES Longitudinal Integrated Clerkship
San Francisco, CA
PROGRAM DESCRIPTION
This Whiteboard Satellite Symposium featuring two leading experts in pediatric epilepsy and genetic neurodevelopmental disorders will be available virtually during the 54th Child Neurology Society Annual Meeting. The session will offer an interactive and visually engaging learning experience through high-definition slides, immersive whiteboard animation, and real-world case presentations. The overall program will provide a comprehensive overview of the latest clinical guidelines and explore best practices for providing individualized treatment for patients with Dravet Syndrome. Additionally, our experts will highlight the latest advances in genetic based therapies—ranging from clinical trial data, potential biomarkers, and the future role of these therapies in routine clinical practice.
TARGET AUDIENCE
This activity is designed to meet the educational needs of pediatric neurologists, pediatric epileptologists, and pediatric nurse practitioners and physician assistants involved in diagnosing and caring for patients with Dravet syndrome.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Assess the pathophysiology, etiology, and clinical manifestations of Dravet syndrome (DS) to categorize accurately.
- Implement strategies that apply current standards of care for DS to optimize disease management and improve the quality of life for patients and their caregivers.
- Adopt evidence-based, expert recommendations regarding genetic testing and the Vineland-3 assessment to effectively diagnose and evaluate patients with DS.
- Summarize the future role of DMTs within the DS treatment landscape, including efficacy and safety data on emerging genetic-based therapies.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Medical Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Linda Laux, MD | Received Research and Consultation fees: Biocodex, Encoded Therapeutics, Praxis Precision Medicines, Stoke Therapeutics, UCB (Union Chimique Belge) |
| Joseph Sullivan, MD, FAES | Received Consulting fees from Praxis, Xenon, Jazz, UCB, Ceribell, Bright Minds, NeuroPace, Biocodex, and Epilepsy Study Consortium. Contracted Research for Stoke Therapeutics, Encoded Therapeutics, Takeda, Zogenix, Neurocrine, and Xenon. Ownership/Stock interest in RSUs and Harmony Biosciences. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Senior VP of Operations for Med Learning Group, has nothing to disclose.
- La Donna Lue Winston, APRN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Shilpa Lalchandani, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Russie Allen, M.M., Outcomes and Accreditation Manager for Med Learning Group, has nothing to disclose.
- Melissa A. Johnson, Program Director for Med Learning Group, has nothing to disclose.
- Millena Papastavrou, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (e.g., physical, dietary, etc.). Please contact Med Learning Group at [email protected]
RELEASED DATE: November 10, 2025
EXPIRATION DATE: November 10, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
